Multiplexed assays for detection of mutations in PIK3CA
- PMID: 18375489
- DOI: 10.1373/clinchem.2007.098376
Multiplexed assays for detection of mutations in PIK3CA
Abstract
Background: Mutations in the PIK3CA gene (phosphoinositide-3-kinase, catalytic, alpha polypeptide) have recently been described in a number of cancers, and their detection is currently limited because of the low sensitivity of conventional sequencing techniques.
Methods: We combined Amplification Refractory Mutation System (ARMS; AstraZeneca) allele-specific PCR and Scorpions (DxS) to develop assays for tumor-borne PIK3CA mutations and used real-time PCR to develop high-throughput multiplexed assays for the most commonly reported PIK3CA mutants (H1047L, H1047R, E542K, E545K).
Results: These assays were more sensitive than sequencing and could detect 5 copies of mutant DNA in proportions as low as 0.1% of the total DNA. We assayed DNA extracted from human tumors and detected PIK3CA mutation frequencies of 10.2% in colorectal cancer, 38.7% in breast cancer, 1.9% in lung cancer, and 2.9% in melanoma. In contrast, sequencing detected only 53% of the mutations detected by our assay.
Conclusions: Multiplexed assays, which can easily be applied to clinical samples, have been developed for the detection of PIK3CA mutations.
Similar articles
-
Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.Asian Pac J Cancer Prev. 2014;15(21):9327-33. doi: 10.7314/apjcp.2014.15.21.9327. Asian Pac J Cancer Prev. 2014. PMID: 25422220
-
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.Int J Cancer. 2008 Mar 1;122(5):1189-94. doi: 10.1002/ijc.23217. Int J Cancer. 2008. PMID: 17990317 Free PMC article.
-
Comparison of Three Real-Time PCR Assays for the Detection of PIK3CA Somatic Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Breast Carcinomas.Pathol Oncol Res. 2019 Jul;25(3):1117-1123. doi: 10.1007/s12253-018-0538-x. Epub 2018 Nov 13. Pathol Oncol Res. 2019. PMID: 30426328
-
Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR.Mol Diagn Ther. 2017 Aug;21(4):443-451. doi: 10.1007/s40291-017-0269-9. Mol Diagn Ther. 2017. PMID: 28247181
-
[What's new liquid biopsy-PIK3CA testing in breast cancer].Pathologe. 2020 Dec;41(Suppl 2):138-142. doi: 10.1007/s00292-020-00868-8. Pathologe. 2020. PMID: 33263809 Review. German.
Cited by
-
PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma.Onco Targets Ther. 2013 May 7;6:497-502. doi: 10.2147/OTT.S41643. Print 2013. Onco Targets Ther. 2013. PMID: 23674897 Free PMC article.
-
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers.PLoS One. 2012;7(11):e47020. doi: 10.1371/journal.pone.0047020. Epub 2012 Nov 7. PLoS One. 2012. PMID: 23144797 Free PMC article.
-
SNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients.PLoS One. 2015 Nov 12;10(11):e0142273. doi: 10.1371/journal.pone.0142273. eCollection 2015. PLoS One. 2015. PMID: 26562020 Free PMC article.
-
Identification of breast cancer-associated PIK3CA H1047R mutation in blood circulation using an asymmetric PCR assay.PLoS One. 2024 Aug 28;19(8):e0309209. doi: 10.1371/journal.pone.0309209. eCollection 2024. PLoS One. 2024. PMID: 39197004 Free PMC article.
-
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.Breast Cancer Res Treat. 2014 Jun;145(2):389-99. doi: 10.1007/s10549-014-2945-3. Epub 2014 Apr 11. Breast Cancer Res Treat. 2014. PMID: 24722917 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous